← All trials
NCT03870438
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2019
- Primary completion
- Dec 31, 2020
- Completion date
- Jun 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of FranceLead sponsor
- University of BergenCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceOverall official - principal investigator
- Centre MurazCollaborator
- University Teaching Hospital, Lusaka, ZambiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.